SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Zmudka Krzysztof)
 

Sökning: WFRF:(Zmudka Krzysztof) > Early abciximab use...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003452naa a2200409 4500
001oai:DiVA.org:liu-57391
003SwePub
008100618s2010 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-573912 URI
040 a (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Siudak, Zbigniewu Jagiellonian University4 aut
2451 0a Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry
264 1b Polish Cardiac Society / TERMEDIA,c 2010
338 a print2 rdacarrier
520 a Background: Primary percutaneous coronary intervention (PCI) is the preferred method of reperfusion in patients with ST elevation myocardial infarction (STEMI). Abciximab is a well established adjunct to primary PCI. The proper timing of abciximab administration in STEMI patients has been investigated in randomised trials, registries and metanalysis, providing conflicting results. Methods: Consecutive data on STEMI patients, transferred for primary PCI in hospital/ambulance STEMI networks between November 2005 and January 2007, from 15 PCI centres in seven European countries was gathered together for a one-year long-term clinical observation (93% rate of completeness). Results: Data from 1,650 patients was collected in the EUROTRANSFER Registry. Abciximab was administered to 1,086 patients (66%), 727 patients received early (at least 30 minutes prior to first balloon inflation) abciximab (EA), and another 359 patients received late abcixirnab (LA). One year mortality was 5.8% in the EA group vs 10.3% with LA (p = 0.007). Adjustment for propensity score methods for EA administration did not change the results, still providing a favourable outcome for the EA group (p = 0.004). It was also revealed that only a minority of patients (36%) were treated within the 90-minute recommended time window from first medical contact to PCI (and 60% for the 120-min time delay). Conclusions: Patients transferred for primary PCI in STEMI hospital networks showed lower rates of death in long-term one-year clinical follow-up when treatment with abciximab was started early.
653 a myocardial infarction
653 a percutaneous coronary intervention
653 a abciximab
653 a registry
653 a MEDICINE
653 a MEDICIN
7001 a Rakowski, Tomaszu Jagiellonian University4 aut
7001 a Dziewierz, Arturu Jagiellonian University4 aut
7001 a Janzon, Magnusu Östergötlands Läns Landsting,Linköpings universitet,Kardiologi,Hälsouniversitetet,Kardiologiska kliniken4 aut0 (Swepub:liu)magja75
7001 a Birkemeyer, Ralfu Villingen Schwenningen, Germany4 aut
7001 a Stefaniak, Justynau Krakow Cardiovasc Research Institute4 aut
7001 a Partyka, Lukaszu Krakow Cardiovasc Research Institute4 aut
7001 a Zmudka, Krzysztofu Jagiellonian University4 aut
7001 a Dudek, Dariuszu Jagiellonian University4 aut
7102 a Jagiellonian Universityb Kardiologi4 org
7730 t KARDIOLOGIA POLSKAd : Polish Cardiac Society / TERMEDIAg 68:5, s. 539-545q 68:5<539-545x 0022-9032
8564 u http://www.kardiologiapolska.pl/y Link to journal
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-57391

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy